← Back to Clinical Trials
Recruiting NCT07215169

NCT07215169 Manual Lymph Drainage for External Lymphedema

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07215169
Status Recruiting
Phase
Sponsor Lund University
Condition Lymphedema of Face
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-10-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
HITLIT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-10-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will evaluate the feasibility of a randomized controlled trial. The future randomized controlled trial will compare two groups following different intensities of manual lymphatic drainage for external head- and neck lymphedema among persons treated with radiotherapy for head- and neck cancer.

Eligibility Criteria

Inclusion Criteria: * • a previous diagnosis of oropharyngeal cancer (all histological types are accepted) * curative treatment with (chemo)radiotherapy to at least 68Gy at the primary site completed no more than 1 year before the study inclusion * age \>18 years * ability to give written and informed consent. Exclusion Criteria: * • pregnancy * surgery or Botox injections in the tissue of the head and neck area * Locoregional deep infection i.e., suspected abscess at the scheduled time points for measurements. * prior daily treatment with Self MLD * other treatment of head and neck lymphedema, for example compression * psychiatric disorders * substance abuse problems

Contact & Investigator

Central Contact

Eva Ekvall Hansson, Professor, RPT

✉ eva.ekvall-hansson@med.lu.se

📞 +46462221986

Principal Investigator

Eva Ekvall Hansson, Professor

PRINCIPAL INVESTIGATOR

Lund University, Medical Faculty, Dep of Health Sciences

Frequently Asked Questions

Who can join the NCT07215169 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphedema of Face. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07215169 currently recruiting?

Yes, NCT07215169 is actively recruiting participants. Contact the research team at eva.ekvall-hansson@med.lu.se for enrollment information.

Where is the NCT07215169 trial being conducted?

This trial is being conducted at Lund, Sweden.

Who is sponsoring the NCT07215169 clinical trial?

NCT07215169 is sponsored by Lund University. The principal investigator is Eva Ekvall Hansson, Professor at Lund University, Medical Faculty, Dep of Health Sciences. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology